Britain and America have hammered out a major bilateral deal that will preserve no tariffs on British pharmaceutical products going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to boost funding on pharmaceuticals through the public health system. This move secures that duties on these vital products will be held at zero for a duration of 36 months.
This agreement follows recent threats to significantly raise duties on patented drug products, with potential rates discussed up to double the cost.
"This deal with the United Kingdom reinforces the international landscape for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a statement said.
Commercial Significance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the America, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to September, the UK sold pharmaceutical products worth £11.1bn to the US. This value made up 17.4% of total UK exports in that timeframe.
"This guarantee safeguards work, increases investment and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," a minister commented.
Specific UK Commitments
The deal includes several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates exceeded 20%.
Industry Background
The pact takes place against a long-running tension between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by arguments that US patients were charged significantly more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward American operations.
One official publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a share of its overall budget over the past decade.
